GALC and Krabbe disease: There are two phase 1/2 non-blinded and non-randomized dose escalation clinical trials for IV delivery of FBX101, an AAVrh.10-mediated gene therapy for GALC replacement, in GLD patients who have already had allogeneic HSCT in the form of UCBT.